ETHCET M SUSPENSION

60 ML WITH MEASURING CUP & PP CAP, PLAIN SILVER, GMP PRINTED, AMBER BOTTLE

ETHCET M SUSPENSION is a combination medication designed to treat various allergy symptoms and respiratory conditions. It contains Levocetirizine Dihydrochloride, a potent antihistamine, and Montelukast Sodium, a leukotriene receptor antagonist. This dual-action formula helps relieve symptoms like sneezing, runny nose, itchy or watery eyes, and breathing difficulties associated with allergic rhinitis and asthma.

ETHCET M SUSPENSION may cause side effects, although not everyone will experience them. Common side effects include:

• Drowsiness or fatigue
• Dry mouth
• Dizziness or headache
• Nausea or gastrointestinal discomfort
• Sore throat
• Increased heart rate (rare)
• Rash (rare)

If any of the following serious side effects occur, consult your doctor immediately:

• Difficulty breathing or swallowing
• Swelling of face, lips, tongue, or throat (signs of an allergic reaction)
• Severe dizziness or fainting

• Adults and Children: The usual dosage for adults and children over 6 years old is 1 teaspoon (5 ml) of the suspension once daily.
• Children under 6 years old: Use only under the direction of a healthcare professional.
• Take the suspension in the evening, preferably after a meal.
• Shake the bottle well before use.

• Pregnancy and Breastfeeding: Consult a doctor before using ETHCET M SUSPENSION during pregnancy or breastfeeding.
• Kidney or Liver Impairment: Special care is needed if you have kidney or liver problems, as the medication may not be fully metabolized and excreted.
• Alcohol Use: Alcohol may increase drowsiness or dizziness, so it is recommended to avoid alcohol while taking this medication.

ETHCET M SUSPENSION should not be used in the following conditions:

• Hypersensitivity to Levocetirizine, Montelukast, or any other ingredients of this formulation.
• Severe renal or liver impairment: Patients with severe kidney or liver dysfunction should not use this medication.
• Acute asthma attacks: This medication is not meant to treat acute asthma attacks. Seek immediate medical help in case of a sudden asthma exacerbation.

• Drowsiness: Levocetirizine may cause drowsiness. Do not drive or operate machinery until you know how this medicine affects you.
• Respiratory Infection: Use with caution if the patient has a current respiratory infection, as Montelukast may sometimes exacerbate symptoms in such cases.
• Tapering Off: If discontinuing the medication, consult your healthcare provider for guidance on tapering off, especially for patients with asthma.

• Adults and Children (above 6 years): The usual dosage is 1 teaspoon (5 ml) once daily.
• Children (under 6 years): Dose adjustment is necessary, based on the healthcare provider’s advice.
• The syrup should be taken in the evening, preferably after a meal.
• Missed Dose: If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed one.

• Alcohol: Increases the sedative effect of Levocetirizine, causing excessive drowsiness.
• CNS Depressants: May enhance the sedative effects of other central nervous system depressants, including sedatives, anti-anxiety medications, and narcotic pain relievers.
• Rifampicin and Erythromycin: May alter the effectiveness of Montelukast.
• Theophylline: Concurrent use with Theophylline may require dose adjustments for optimal therapeutic effect.

• Shake the bottle well before each use to ensure the correct dosage.
• Store at room temperature, away from direct sunlight, and out of reach of children.
• Do not exceed the recommended dosage unless instructed by a doctor.

• Packaging: Available in a 100 ml bottle.
• Form: Syrup
• Price: Available upon request from pharmacies.
• Shelf Life: 2 years from the manufacturing date.

• Ducharme, F. M., & Lemire, C. (2010). Montelukast in the treatment of asthma and allergic rhinitis. Canadian Respiratory Journal, 17(3), 147-154.
• Greig, R. (2008). The safety and efficacy of Levocetirizine in the management of allergic rhinitis. Drugs, 68(12), 1577-1586.
• National Institute for Health and Care Excellence (NICE). (2018). Allergic Rhinitis: Management in Primary Care. NICE Guidelines.